NCT02112864

Brief Summary

Post thoracotomy pain syndrome still affects 50% of patients after a thoracic surgery. Pathogenesis is unclear but there is growing evidence that neuro inflammation may play a significant role. Dexamethasone is a very potent anti-inflammatory drug. The hypothesis of this study is that dexamethasone, given pre operatively, would help reduce the incidence of post thoracotomy pain syndrome 3 months after surgery, by reducing the inflammatory response, in patients undergoing elective thoracic surgery that includes thoracic epidural analgesia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P50-P75 for not_applicable chronic-pain

Timeline
Completed

Started May 2014

Longer than P75 for not_applicable chronic-pain

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 9, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 14, 2014

Completed
17 days until next milestone

Study Start

First participant enrolled

May 1, 2014

Completed
10.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

March 20, 2023

Status Verified

March 1, 2023

Enrollment Period

10.6 years

First QC Date

April 9, 2014

Last Update Submit

March 17, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • cytokine elevation

    24 h after surgery

Secondary Outcomes (8)

  • incidence of post thoracotomy pain syndrome

    3 months after surgery

  • incidence of post thoracotomy pain syndrome

    6 months after surgery

  • incisional and shoulder pain

    acute post operative period

  • Brief pain inventory questionnaire

    three months after surgery

  • Brief pain inventory questionnaire

    6 months after surgery

  • +3 more secondary outcomes

Study Arms (2)

dexamethasone 10 mg

EXPERIMENTAL

Dexamethasone 10 mg will be given as a single-dose, pre incision, intravenously

Drug: Dexamethasone

normal saline

PLACEBO COMPARATOR

Patients in this group will receive 2.5 mL of normal saline intravenously, pre-incision

Drug: Normal Saline

Interventions

10 mg (2.5 ml)

Also known as: decadron
dexamethasone 10 mg

2.5 mL normal saline

Also known as: Placebo
normal saline

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • elective thoracic surgery using a thoracotomy incision and thoracic epidural analgesia
  • ASA I-III
  • age 18-75 yo

You may not qualify if:

  • contra-indication to thoracic epidural analgesia
  • patient refusal
  • patients already taking cortisone or dexamethasone
  • patients on chronic opioid medication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maisonneuve-Rosemont Hospital

Montreal, Quebec, H1T 4M5, Canada

RECRUITING

MeSH Terms

Conditions

Chronic Pain

Interventions

DexamethasoneCalcium DobesilateSaline Solution

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedBenzenesulfonatesBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsArylsulfonatesArylsulfonic AcidsSulfonic AcidsSulfur AcidsSulfur CompoundsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Veronique Brulotte, MD, Msc

    Maisonneuve-Rosemont Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Véronique Brulotte, MD, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D., M.Sc.

Study Record Dates

First Submitted

April 9, 2014

First Posted

April 14, 2014

Study Start

May 1, 2014

Primary Completion

December 1, 2024

Study Completion

July 1, 2025

Last Updated

March 20, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will share

Locations